Get the Stockscreener App
2.25
0.45%
0.010
Pre-market:
2.26
0.010
+0.44%
Nautilus Biotechnology Inc stock is traded at $2.25, with a volume of 346.06K.
It is up +0.45% in the last 24 hours and down -10.36% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$2.24
Open:
$2.29
24h Volume:
346.06K
Relative Volume:
0.89
Market Cap:
$285.93M
Revenue:
-
Net Income/Loss:
$-57.09M
P/E Ratio:
-4.9812
EPS:
-0.4517
Net Cash Flow:
$-51.43M
1W Performance:
-3.43%
1M Performance:
-10.36%
6M Performance:
+18.42%
1Y Performance:
+220.97%
1-Day Range:
$2.245
$2.32
1-Week Range:
$2.205
$2.4199
52-Week Range:
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.25 | 285.93M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology (NAUT) Shows Modest Gains Amid Tight Trading RangeNaked POC - newsline.com
Nautilus Biotechnology (NAUT) Edges Higher Amid Biotech Sector Gains; Resistance Test in FocusForce Index - newsline.com
Nautilus Biotechnology (NAUT) Plunges 10.8% as Bearish Momentum BuildsLow Risk Entry Stocks - newsline.com
NAUT Stock Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Tau proteoform quantification research unveiled by Nautilus Biotechnology at ASMS2026 - Traders Union
Andreessen Horowitz (NAUT) funds sell 5M shares, retain near-10% stake - Stock Titan
Andreessen Horowitz funds trim Nautilus (NAUT) stake with 5M-share open-market sale - Stock Titan
Nautilus Biotechnology promotes single molecule proteomics at ASMS with Voyager platform experts - Traders Union
NAUT News | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Surges 5.4% as Biotech Sector Momentum BuildsIntraday Profile - The Legal Advocate
Nautilus Biotechnology (NAUT) Surges Over 5% as Small-Cap Biotech Shows Renewed StrengthMoney Flow - newsline.com
NAUT Q1 2026 Earnings: Narrowed Losses Beat Estimates Amid Platform ProgressEPS Miss Report - The Legal Advocate
Nautilus Biotechnology (NAUT) Pulls Back: Key Levels to Watch After 3.9% DeclineEnding Diagonal - The Legal Advocate
Nautilus Biotechnology (NAUT) Holds Steady at $2.54 as Stock Consolidates Near Key LevelsLow Volatility Picks - Newser
NAUT Stock Price, Quote & Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Q1 2026 Earnings Surprise: EPS $-0.12, Up SignificantStock Analysis Community - Newser
Nautilus Biotechnology Decline Means Insider Profits Down To US$432k - Moomoo
Nautilus Biotechnology introduces Voyager Platform for precise tau proteoform analysis - Traders Union
TradingKey - TradingKey
Nautilus Biotechnology unveils Voyager Platform for quantifying 768 tau proteoforms at Tau Global 2026 - Traders Union
NAUT (Nautilus Biotechnology) quarterly results under review as market awaits full earnings disclosure and segment analysis.Social Buzz Stocks - Newser
Why Nautilus Biotechnology (NAUT) ability to execute stands out (Market Focus) 2026-05-06Fibonacci Fan - thelegaladvocate.com
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
3 Promising Penny Stocks With Market Caps Up To $900M - simplywall.st
Nautilus Biotechnology (NAUT) price target increased by 60.00% to 4.08 - MSN
Nautilus expects cash runway through 2027 while targeting oncology early access in H2 2026 - MSN
What revision trend Nautilus Biotechnology (NAUT)? (Spikes) 2026-05-01Revenue Growth Stocks - newsline.com
Guggenheim Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Nautilus Biotechnology (NAUT) outlines 2026 shareholder votes on directors, pay and auditor - Stock Titan
Nautilus Biotechnology (NASDAQ: NAUT) details Q1 2026 loss and cash runway - Stock Titan
Nautilus Biotechnology Plans Voyager Platform Launch for Late 2026 - HarianBasis.co
Nautilus Biotechnology Q1 Earnings Call Highlights - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Nautilus Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Nautilus Biotechnology Reports First Quarter 2026 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast - Investing.com
Earnings call transcript: Nautilus Biotechnology beats Q1 2026 EPS forecast By Investing.com - Investing.com Canada
Nautilus Biotechnology Q1 net loss narrows as expenses fall - TradingView
Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Q1 2026: Nautilus Biotechnology (NASDAQ: NAUT) cuts costs and narrows loss - Stock Titan
Nautilus Biotechnology 10-Q: $0.0M Revenue, $(0.12) EPS for Q1 2026 - TradingView
Sentinel Trust Co. LBA Purchases New Position in Nautilus Biotechnology, Inc. $NAUT - MarketBeat
Nautilus Biotechnology Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Nautilus Biotechnology launches recruitment drive for Iterative Mapping Early Access Program - Traders Union
Here is why Nautilus Biotechnology (NAUT) is one of the best life sciences penny stocks to buy - MSN
Nautilus Biotechnology CEO joins Biocom panel on AI impact in biotech sector - Traders Union
Nautilus Biotechnology (NAUT) Expected to Announce Earnings on Tuesday - MarketBeat
Nautilus Biotechnology (NAUT) Stock: Fair Value Assessment (Institutional Selling) 2026-04-20High Beta Stocks - Xã Vĩnh Công
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):